Skip to main content

Table 4 Characteristics of follicular and mature nodal peripheral T-cell lymphomas in outpatient and inpatient cohorts

From: Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain

 

Follicular lymphoma (N = 562)

Nodal peripheral T-cell lymphoma (N = 261)

Characteristic

OPs 1 (n = 439)

IP 2 (n = 123)

P value 1 vs 2

OPs 1 (n = 160)

IP 2 (n = 101)

P value 1 vs 2

Age (years), mean (SD)

61.1 (18.4)

65.6 (13.6)

<.001

62.1 (14.3)

68.5 (12.4)

<.001

  ≤ 60, n (%)

212 (48.3)

40 (32.5)

<.001

75 (46.9)

21 (20.8)

<.001

  > 60, n (%)

227 (51.7)

83 (67.5)

<.001

85 (53.1)

80 (79.2)

<.001

Sex, n (%)

      

 Females

224 (51.0)

59 (48.0)

.071

67 (41.9)

38 (37.6)

.066

 Males

215 (49.0)

64 (52.0)

.074

93 (58.1)

63 (62.4)

.068

Clinical manifestations, n (%)

 Lymphadenopathy

356 (81.1)

82 (66.7)

<.001

91 (56.9)

39 (38.6)

<.001

 Systemic symptoms

52 (11.8)

19 (15.4)

.058

54 (33.8)

47 (46.5)

<.001

 Pain symptoms

13 (3.0)

9 (7.3)

.037

10 (6.3)

13 (12.9)

<.001

 Chest symptoms

12 (2.7)

8 (6.5)

.054

3 (1.9)

1 (1.0)

.211

 Other symptoms/signs

6 (1.4)

5 (4.1)

.086

2 (1.3)

1 (1.0)

.235

Successive/first visit ratio

2.10

  

2.66

  

QDU time for diagnosis /admission time for diagnosis (days), mean (SD)

15.8 (1.8)

11.5 (2.3)

.002

18.3 (2.4)

14.9 (3.0)

.007

Suspected/compatible lymphoma by FNAC, n (%)/total n

230 (68.5)/336

33 (70.2)/47

.143

45 (58.4)/77

19 (57.6)/33

.215

Time to FNAC (days), mean (SD)

1.4 (0.7)

1.3 (0.5)

.120

1.1 (0.6)

1.2 (0.4)

.184

Time to excisional biopsy (days), mean (SD)

7.6 (1.5)

3.8 (1.0)

.006

7.2 (1.3)

2.9 (0.8)

<.001

ECOG performance score > 1, n (%)/total n

24 (5.7)/418

12 (10.4)/115

.031

48 (31.6)/152

37 (37.8)/98

.020

B symptoms, n (%)

61 (13.9)

24 (19.5)

.020

90 (56.3)

64 (63.4)

<.001

Serum LDH > UNL, n (%)

92 (21.0)

34 (27.6)

.003

96 (60.0)

69 (68.3)

<.001

Extranodal disease, n (%)

38 (8.7)

14 (11.4)

.093

   

> 1 extranodal site, n (%)

   

63 (39.4)

52 (51.5)

<.001

Histologic grading, n (%)

 1

123 (28.0)

33 (26.8)

.157

   

 2

172 (39.2)

48 (39.0)

.208

   

 3A

114 (26.0)

36 (29.3)

.063

   

 Unspecified

30 (6.8)

6 (4.9)

.135

   

Ann Arbor stage, n (%)

 I-II

156 (35.5)

38 (30.9)

.033

36 (22.5)

14 (13.9)

<.001

 III-IV

283 (64.5)

85 (69.1)

.034

124 (77.5)

87 (86.1)

<.001

FLIPI score, n (%)/total n

 Low risk (0-1)

165 (37.6)/439

41 (33.3)/123

.040

   

 Intermediate risk (2)

153 (34.9)/439

43 (35.0)/123

.214

   

 High risk (3-5)

121 (27.6)/439

39 (31.7)/123

.049

   

IPI score, n (%)/total n

 Low risk (0-1)

   

30 (19.7)/152

13 (13.3)/98

.008

 Intermediate risk (2-3)

   

75 (49.3)/152

47 (48.0)/98

.179

 High risk (4-5)

   

47 (30.9)/152

38 (38.8)/98

<.001

  1. Abbreviations: FLIPI follicular lymphoma international prognostic index
  2. For other abbreviations, definitions, and explanations, see Tables 1 and 3
  3. Missing data: variables ‘time to FNAC’ (follicular lymphoma: OPs = 8, IPs = 5; nodal peripheral T-cell lymphoma: OPs = 4, IPs = 3), ‘time to excisional biopsy’ (follicular lymphoma: OPs = 2, IPs = 2; nodal peripheral T-cell lymphoma: OPs = 1, IPs = 0), ‘B symptoms’ (follicular lymphoma: OPs = 2, IPs = 0; nodal peripheral T-cell lymphoma: OPs = 3, IPs = 2)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us